Qingdao Primedicine Pharmaceutical Technology Co., Ltd. is a high-tech enterprise emphasizing on the research and development of first-in-class new drugs, and the development and commercialization of innovative drugs related to the central nervous system in the treatment of drug addiction, Alzheimer's disease, cerebral stroke, depression, schizophrenia, myocardial infarction, etc.

Primedicine Pharmaceutical was established in September 2016 and is situated in the beautiful coastal city of Qingdao. It is the first full-time overseas academician team in Qingdao International Academician Park. Wang Yutian, Fellow of The Royal Society of Canada is the Chairman and the Chief Scientist of the company. The majority of the company’s team members have overseas educational background and work experience. The core members have world-class scientific research ability and extensive experience in clinical medical treatment and pharmaceutical management.

The company’s current research product pipeline includes PMS-001 (AMPA receptor modulator), PMS-002 (NMDA receptor subtype allosteric modulator), PMS-003 (SREBP-1 inhibitor), PMS-004 (JNK kinase inhibitor), etc. Most of the compounds are a result of independent research and innovation by the company’s determined scientific and technological teams, and are protected under global patents.